NGS Medical Policy Revision

National Government Services Medical Policy Revision for: Drugs and Biologicals, Coverage of, for Label and Off Label Uses
LCD and Coverage Articles Part A & B Effective January 1, 2009
Posted on NGS January 26, 2009

LCD for Drugs and Biologicals, Coverage of, for Label and Off-Label Uses (L25820)R5* (effective 01/01/2009); Internal; the LCD has been revised to include compendia recognized by CMS based on Change Request 6191 (Compendia as Authoritative Sources for Use in the Determination of a Medically Accepted Indication of Drugs and Biologicals Used Off-Label in an Anti-Cancer Chemotherapeutic Regimen. Added Internet Only Manual (IOM) language to the “Limitations” section. The following articles have been added: A48208 - Filgrastim, Pegfilgrastim (e.g., Neupogen®, Neulasta TM), A48339 – Floxuridine, A48211 - Thyrotropin Alfa (Thyrogen®) and A48213 - Vitamin B-12 Injections. The following article has been retired: A46093 – Rituximab (Rituxan®). Minor changes were made to reflect current template language. Although revision R5 is effective 01/01/2009, the addition of the compendia based on Change Request 6191 is effective 11/25/2008. No notice period required and none given.

Link to Article